Previous Article | Next Article 
Mol Cell Biol, April 1998, p. 1911-1918, Vol. 18, No. 4
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Differential Screen for Ligand-Regulated Genes:
Identification of HoxA10 as a Target of Vitamin
D3 Induction in Myeloid Leukemic Cells
Nynke Y.
Rots,
Min
Liu,
Eric C.
Anderson, and
Leonard P.
Freedman*
Cell Biology Program, Memorial
Sloan-Kettering Cancer Center, New York, New York 10021
Received 21 October 1997/Returned for modification 4 December
1997/Accepted 9 January 1998
 |
ABSTRACT |
1,25-Dihydroxyvitamin D3
[1,25(OH)2D3], the hormonal ligand for
vitamin D3, is a potent inducer of myeloid-leukemic-cell
differentiation. Such cells differentiate exclusively into
monocytes/macrophages in response to this ligand. Since
1,25(OH)2D3 transduces its hormone signal
through the vitamin D3 receptor (VDR), a ligand-modulated transcription factor and member of the nuclear hormone receptor superfamily, we sought to identify direct VDR target genes induced during this differentiation process. To do so, we applied a modified differential screen with a nascent-RNA purification strategy using biases for immediate-early-response genes induced by
1,25(OH)2D3 in the myelomonocytic cell line
U937. Using this screen, we had previously identified
p21Waf1/Cip1 as a gene transcriptionally
induced by 1,25(OH)2D3 and demonstrated that
this induction facilitates the differentiation of U937 cells into
monocytes/macrophages (24). Here, we describe in detail our differential screen strategy and the identification and isolation of 20 1,25(OH)2D3-inducible genes or unknown cDNAs by
means of this screen. One gene newly identified as a target of VDR
regulation in myeloid cells is the homeobox HoxA10 gene.
HoxA10 protein may act as a general regulator of cell growth, since
overexpression of HoxA10 facilitated the differentiation of U937 cells
into monocytes/macrophages independent of
1,25(OH)2D3 and acted to strongly inhibit the
growth of the breast cancer cell line MCF-7 by arresting these cells in
G1.
 |
INTRODUCTION |
The processes of cellular
proliferation and the progressive acquisition of a specialized
phenotype show a remarkable degree of coordination. The essentially
hierarchical nature of development and tissue maintenance is elegantly
displayed in the replenishment of the hematopoietic system of the adult
vertebrate. All the various types of blood and lymph cells are derived
during fetal and adult life from a common pluripotent hematopoietic
stem cell. These stem cells are rare in bone marrow (0.01% of bone
marrow cells), and a large proportion of primitive stem cells are
quiescent. A small number of multipotent stem cells laid down during
embryogenesis give rise to a much larger population of more
developmentally restricted progenitor cells. These cells then
proliferate further to produce the functional, mature, postmitotic
cells required to replace those cells lost through natural processes
(e.g., apoptosis, postterminal differentiation). The stem cells
themselves are capable of self-renewal to replace those that become
committed to differentiation. It is clear that a balance in cell types
and numbers is maintained throughout this progression from a less to a
more differentiated state.
Leukemia is defined as the uncontrolled proliferation or expansion of
hematopoietic cells that do not retain the capacity to differentiate
normally into mature blood cells. Some hematologic disorders are not,
strictly speaking, leukemias because they display only part of the full
leukemic phenotype
either growth expansion (myeloproliferative
syndromes and chronic-phase chronic myelogenous leukemia) or
differentiation block (myelodysplasia syndrome); yet both of these
conditions can progress to acute leukemia (26). This
observation suggests that full leukemic transformation requires defects
in both growth and differentiation. Several compounds and hormones,
however, are capable of reversing this transformation by inducing
leukemic cells to undergo differentiation (in some cases by growth
arresting cells in G1; see below). For example, 1,25-dihydroxyvitamin D3
[1,25(OH)2D3], the active metabolite of
vitamin D3, is a potent inducer of myeloid-leukemic-cell
differentiation. Abe et al. (1) first reported that in
vitro, murine myeloid leukemia M1 cells could be induced to
differentiate into cells that were functionally and morphologically
similar to macrophages by using 10
10 to 10
8
M 1,25(OH)2D3. The same group showed that
treatment with this secosteroid in vivo considerably prolonged the
survival of mice inoculated with M1 cells (15). Subsequent
studies have established that
1,25(OH)2D3 could induce monocytic
differentiation in human myeloid leukemic cell lines (27)
and in blasts from patients with acute myeloid leukemia (14)
or myelodysplasia syndrome (16). In animals and patients,
however, differentiation occurs only at high concentrations of
1,25(OH)2D3 (10 to 100 nM), thus limiting the
potential therapies as a result of the toxicity of this hormone (it
induces hypercalcemia by stimulating calcium absorption) at nanomolar
concentrations (17).
1,25(OH)2D3 transduces its signal through the
vitamin D3 receptor (VDR), a member of a large group of
related, transcriptional regulatory proteins that comprise the nuclear
receptor superfamily. 1,25(OH)2D3-mediated
effects on myeloid-cell differentiation ought therefore to be initiated
through the transcriptional regulation of specific VDR target genes. To
isolate such genes, we carried out a modified differential screen with
a nascent-RNA purification strategy (6, 35) that biases
for immediate-early-response genes that are induced by
1,25(OH)2D3 in the myelomonocytic cell line
U937. The first gene isolated by means of this screen was p21Waf1/Cip1, which was subsequently shown in
fact to be transcriptionally induced by
1,25(OH)2D3; this induction facilitates the
differentiation of U937 cells into monocytes/macrophages
(24). This strongly suggested that our differential screen
satisfied two important criteria: it enriched for genes directly under
the control of VDR, and the genes in question encoded proteins that
play key roles in the induction of myeloid-cell differentiation.
Here, we describe our differential-screen strategy in detail, identify
20 1,25(OH)2D3-inducible genes or unknown cDNAs
that we have isolated with this screen, and characterize one such gene as a newly identified target of VDR regulation in myeloid cells. The
product of this gene, HoxA10, may act as a general regulator of cell
growth, since its overexpression facilitates the differentiation of
U937 cells into monocytes/macrophages independent of
1,25(OH)2D3 and acts to strongly inhibit the
growth of the breast cancer cell line MCF-7 by arresting these cells in
G1.
 |
MATERIALS AND METHODS |
Cell culture and plasmids.
U937 human myelomonocytic cells
(clone 4; provided by K. Nilsson [29]) were routinely
maintained in RPMI 1640 medium supplemented with 10% fetal bovine
serum and 5 mM L-glutamine. MCF-7 human breast
adenocarcinoma cells were propagated in Eagle's minimum essential
medium with nonessential amino acids and 10% fetal bovine serum.
pCMV5-HoxA10 was produced by inserting full-length HoxA10 as an
EcoRI fragment generated from pBS-HoxA10 (a generous gift of
C. Largman) into the EcoRI site of pCMV5.
Total nascent RNA preparation.
The isolation of newly
synthesized mRNA during 1,25(OH)2D3 induction
was based on a previously described protocol (6, 35). U937
cells at a density of 0.5 × 106 cells/ml were treated
with 1.0 × 10
7 M
1,25(OH)2D3 (a gift from M. Uskokovic, Hoffman
LaRoche) or ethanol, together with 10 µg of cycloheximide/ml, 200 mM
4-thiouridine (Sigma Chemicals), and 2.5 µCi of
[3H]uridine/ml for 4 h. Total cellular RNA (400 µg) was then resuspended in 1 ml of pyrocarbonic acid diethyl
ester-H2O. One milliliter of 2× buffer A (0.1 M sodium
acetate [pH 5.5], 0.2% sodium dodecyl sulfate (SDS), 0.3 M NaCl, and
8 mM EDTA) was added, heat denatured for 5 min at 65°C, and then
cooled on ice. A 6.0-ml volume of Affi-gel 501 (Bio-Rad) matrix was
washed with 10 column volumes of buffer A. RNA was loaded onto the
column and incubated for 10 min at room temperature, and the
flowthrough was collected. Three column volumes of buffer A and 3 column volumes of buffer A plus 0.5 M NaCl were used to wash the
column. Thiol-labeled RNA was then eluted with 18 ml of buffer A plus
2-mercaptoethanol by collecting 12 fractions of 1.5 ml each. Aliquots
(40 µl) of each fraction were then counted to monitor recovery of
RNA. Peak fractions of RNA were precipitated by adding sodium acetate
and ethanol, and RNA was quantitated by absorbance at 260 and 280 nm.
Peak RNA recovered in the thiouridine fractions was approximately 5 to
8% of the input RNA. Poly(A)+ RNA was generated from the
total nascent RNA by one round of oligo(dT) chromatography with the
Fast-Track Kit (Invitrogen), following the manufacturer's
specifications.
cDNA library construction and differential screening.
Five
micrograms of pBluescript II SK+ (Stratagene) plasmid DNA
was digested by EcoRI and XhoI and then
dephosphorylated by calf intestine phosphatase (Boehringer Mannheim)
and gel purified. The recovered vector DNA was aliquoted and stored at
20°C. Five micrograms of the
1,25(OH)2D3-treated nascent mRNA from U937
cells was used as the source of cDNA for library construction following the manufacturer's instructions. The distribution of radioactive tracer cDNA was from 300 to 7,000 bp, and the yield of cDNA was determined by trichloroacetic acid precipitation. EcoRI
linkers containing non-self-complementary overhangs were ligated into the cDNA, which was subsequently size fractionated to recover fragments
over 500 bp in length. cDNA-plasmid ligation was set up with 50 to 100 ng of cDNA and 10 to 20 ng of vector. Following incubation at 16°C
overnight, the ligation reaction was diluted fourfold with sterile
H2O, and a small portion of the library (one tenth) was
transformed into Epicurian Escherichia coli XL2-blue MRF'
ultracompetent cells (Stratagene) by means of the supplier's recommended protocol. Eighteen clones were randomly picked and examined
by EcoRI-XhoI digestion; 100% of the clones had
inserts, ranging in size from 500 to 2,000 bp.
For differential colony screening, transformation mixtures were plated
directly onto nitrocellulose filters overlaid onto Luria-Bertani
agar-ampicillin plates, each 150-mm-diameter dish containing
approximately 5,000 to 6,000 clones. Two carefully marked replicate
filters were prepared by direct transfer of bacterial colonies onto a
second prewetted nitrocellulose filter. A master plate and two filters
were prepared in this manner from each plate. The initial screen was
made up of about 100,000 unamplified clones
approximately one-fifth of
the cDNA library. The colonies were grown directly on the
nitrocellulose for 8 h at 37°C. Each filter was then transferred to an agar plate containing 100 µg of chloramphenicol per ml to amplify the plasmid. After 3 h at 37°C, the colonies were lysed. The remainder of the transformation mix was plated out and grown overnight. The following morning, the bacterial colonies were scraped
in a batch with 30 ml of Luria-Bertani agar-ampicillin, and 1.0-ml
aliquots were stored at
70°C. The filters were treated with 0.5 M
NaOH-1.5 M NaCl, neutralized in 0.5 M Tris-HCl (pH 7.5), rinsed in 2×
SSPE (1× SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7]), and air dried. The DNA was immobilized on
the filters by UV cross-linking (Strategene) and then baked at 80°C
in a vacuum oven for 2 h.
To generate positive and negative probes, 2 µg of nascent
poly(A)+ RNA from each treatment was used to synthesize a
single-stranded cDNA probe with a high specific activity by using
Superscript Reverse Transcriptase II (BRL) and
[
-32P]dCTP. The size distribution of the total
32P-cDNA was examined by electrophoresis on a 1% alkaline
agarose gel. The filters were prehybridized for at least 2 h at
42°C in 50% formamide, 6× SSPE, 5× Denhardt's solution, 1% SDS,
and 100 µg of poly(A) · poly(C). The hybridization was carried
out for 72 h at 42°C under the same conditions except with a
final probe concentration of 2.0 × 106 cpm/ml. One of
the duplicate filters from each dish was hybridized to the positive
probe [+1,25(OH)2D3], and the other duplicate was hybridized to the negative probe
[
1,25(OH)2D3]. The filters were washed
twice at room temperature for 30 min per wash with 2× SSPE-0.1% SDS
and then once at room temperature for 30 min with 0.2× SSPE-0.1%
SDS. The final wash was carried out at 50°C with 0.1× SSPE and 0.1%
SDS for 30 min. After autoradiography, the positive and negative films
were superimposed and compared at each spot. From the primary screen
(0.1 × 106 unamplified clones), approximately 4,000 colonies that exhibited differential hybridization to the stimulated
and unstimulated probes were picked and grown in 96-well plates.
Duplicate dot blots were prepared with a replicator-beaded lid (TSP;
Nunc) on HATF membranes (Millipore) from each plate and hybridized
again with the positive and negative
1,25(OH)2D3 cDNA probes as in the primary
screen. Candidates (approximately 200) which still appeared to be
differentially expressed after the secondary screen were isolated for
Northern blot analysis.
Northern blot analysis.
Total RNA (20 µg) from 0-, 4-, and
12-h treatments of U937 cells with 1,25(OH)2D3
were subjected to electrophoresis on a 1.2% formaldehyde-agarose gel
and transferred to nylon membranes (NEN Genescreen Plus; New England
Biolabs) by capillary action. Hybridization was carried out in a
solution of 50% formamide, 2× Denhardt's solution, 5× SSPE, 5%
dextran sulfate, and 0.1% SDS at 42°C for 24 h, followed by
washes: twice in 2× SSPE plus 0.1% SDS at room temperature for 15 min, once in 0.1× SSPE plus 0.1% SDS at room temperature for 15 min,
and once in 0.1× SSPE plus 0.1% SDS at 50 to 65°C for 30 min.
Probes from all of the unknown clones were prepared by PCR from the
pBluescript vector with T3 and T7 primers. The amplified products were
then gel purified and radioactively labeled with
[
-32P]dCTP by random priming.
Clones whose RNA was induced in the Northern blots were partially
sequenced with the T3 primer from pBluescript (pBluescript II
SK+ was used to create the original cDNA plasmid library
from 1,25(OH)2D3-treated U937 cells). Sequence
data was analyzed by means of the BLAST algorithm, and both the DNA and
the translated sequences were assessed for identities and/or homologies
to known genes or proteins.
Nuclear run-on assay.
Uninduced and induced
[10
7 M 1,25(OH)2D3] U937 cells
were harvested, washed twice in phosphate-buffered saline, and lysed in Nonidet P-40 lysis buffer (10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 3 mM
MgCl2, and 0.5% [vol/vol] Nonidet P-40). The lysed cells were spun for 5 min at 50 × g, after which the nuclei
were resuspended in 100 µl of glycerol storage buffer (40%
[vol/vol] glycerol, 50 mM Tris-HCl [pH 8.3], 5 mM
MgCl2, and 0.1 mM EDTA). To 100 µl of nuclei, 100 µl of
2× reaction buffer (10 mM Tris-HCl [pH 8.0], 5 mM MgCl2,
0.3 M KCl), 5 mM concentrations of each nucleotide (ATP, CTP, and GTP),
and 10 µl of 10-mCi/ml [
-32P]UTP (3,000 Ci/mmol;
Amersham) were added. The reaction mixture was incubated for 30 min at
30°C, the reaction was terminated by the addition of 40 U of
RNase-free DNase I in HSB buffer (0.5 M NaCl, 50 mM MgCl2,
2 mM CaCl2, and 10 mM Tris-HCl [pH 7.4]), and the mixture
was further incubated at 30°C for 5 min. After the addition of 200 µl of SDS-Tris buffer and 10 µl of proteinase K (20 mg/ml), the
reaction was incubated for another 30 min at 42°C. RNA was extracted,
precipitated, and dissolved in
N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES)
solution (10 mM TES [pH 7.4], 10 mM EDTA, and 0.2% [wt/vol] SDS).
The RNA was hybridized to HoxA10 cDNA immobilized on a
nitrocellulose membrane for 36 h at 65°C. Strips were washed with 2× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate), dried, and exposed to X-ray film.
-Actin cDNA was used as a control.
Immunoblots.
Total cell extracts were resolved by 15 to
7.5% SDS-polyacrylamide gel electrophoresis and transferred to a
polyscreen polyvinylidene difluoride transfer membrane (NEN).
Blots were incubated with a polyclonal anti-HoxA10 rabbit antibody
(Babco) and developed by the use of enhanced chemiluminescence
(Amersham).
Transfection and flow cytometry.
A total of 107
early-log-phase U937 cells were transiently cotransfected with 10 µg
of pCMV5 vector with or without specific insert cDNAs and 8 µg of
pGreen Lantern-1, a plasmid containing a modified version of the
reporter gene Gene Fluorescent Protein (GFP) (Gibco-BRL) (for clarity,
this plasmid is called pCMV-GFP throughout this work). Cells were
harvested, washed twice, resuspended in 400 µl of RPMI 1640, electroporated (2,800 µF and 250 V; BTX) in 4-mm cuvettes, and
diluted in 20 ml of RPMI 1640 complete medium containing 10% fetal
calf serum. Forty-eight hours later, cells were harvested, filtered
through cotton to remove dead cells, and analyzed by a
fluorescence-activated cell sorter (FACS) (Becton Dickinson) with
phycoerythrin-conjugated CD11b (Caltag). Only GFP-positive cells were
taken into account for the analysis. For MCF-7 transfections,
107 MCF-7 cells (60 to 80% confluent) were cotransfected
with 2 µg of pCMV-GFP and 8 µg of empty pCMV5 vector or
pCMV5-HoxA10 by means of electroporation (1,000 µF, 100 V) as
just described. Forty-eight hours after electroporation, cells were
harvested, washed two times with phosphate-buffered saline, and
resuspended in minimum essential medium without additions. GFP-positive
cells were sorted (Becton Dickinson), and the DNA contents of their isolated nuclei were then determined by flow cytometry.
 |
RESULTS |
A differential screen to enrich for
1,25(OH)2D3-inducible genes.
We sought to
isolate and clone 1,25(OH)2D3-regulated
genes that might initiate the differentiation of U937 cells
in response to the ligand. To do so, we designed a modified
differential screen that would bias for direct-transcriptional-target
genes of VDR. As outlined in Fig. 1,
three strategies were jointly employed to increase the likelihood of
having an immediate-early transcript induced by
1,25(OH)2D3 represented in the probes and the
cDNA library, as well as to increase the sensitivity of differential hybridization. First, since a 4-h pulse of the ligand was sufficient to
commit U937 cells to differentiate along a monocyte/macrophage pathway
(23a), cells that were harvested to generate the cDNA library and as sources of the induced positive probe were treated with
1.0 × 10
7 M 1,25(OH)2D3 for
no more than 4 h, thus limiting the number of activated downstream
genes (i.e., those not directly regulated by VDR) that would be
represented in the library or probes. Second, in both the
1,25(OH)2D3-treated and the untreated cell
populations, cycloheximide was included to inhibit protein synthesis
and thereby preclude indirect effects of the ligand. Because
cycloheximide was used in the library and in the preparation of both
the induced and the uninduced probes, differential expression of
putative clones observed upon colony screening should not be due
to the effects of this drug, and therefore the possibility of cloning only cycloheximide-inducible genes is eliminated. Third, 4-thiouridine, together with a [3H]uridine tracer, was added to
cells during the 4-h 1,25(OH)2D3 treatment to enrich for nascent-mRNA transcripts that could be selectively purified by organo-mercury chromatography (35). In this way, newly synthesized transcripts [e.g., those made during the 4-h 1,25(OH)2D3 pulse] could be enriched
by separating them from the preexisting, housekeeping-type gene
transcripts which could lower the relative abundances of the induced
genes.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
A differential screening strategy for the isolation of
VDR target genes upregulated during the induced differentiation of U937
cells. See text for details. CHX, cycloheximide; Vit. D, vitamin
D3.
|
|
To this end, total cellular RNA accumulated in either the presence or
absence of 1,25(OH)2D3 was fractionated by
passage through an affinity phenyl-mercury agarose column such that
thiol-labeled transcripts were covalently bound to the column, while
unlabeled RNA was collected in the flowthrough (Fig.
2A). Nonspecifically bound RNA was
removed from the column by low- and high-salt washes, and the
thiol-labeled RNA was subsequently eluted in the presence of 50 mM
2-mercaptoethanol. Typically, about 95% of the total RNA input was
recovered in the flowthrough and nonspecifically bound column fractions
(Fig. 2A). When the nonselected total RNA was compared with the
thiol-selected RNA by Northern hybridization with a probe encoding
CD14, a gene known to be induced by 1,25(OH)2D3 in U937 cells, a dramatic increase in the relative abundance of CD14
transcripts was observed in the thiol-selected RNA (Fig. 2B). This
result demonstrates our method to be an effective enrichment of newly
synthesized U937 transcripts during a 4-h
1,25(OH)2D3 pulse.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Purification of thiol-labeled, nascent mRNA. (A)
Affinity column profile of the nascent-RNA selection. A total of 400 µg of cellular RNA was isolated from U937 cells treated with
1,25(OH)2D3 and cycloheximide for 4 h.
This RNA was applied to a phenyl-mercury agarose column (Affi-gel 501).
The column was washed extensively, and thiol- and
[3H]uridine-labeled transcripts were eluted as described
in Materials and Methods. (B) Enrichment of
1,25(OH)2D3-induced nascent mRNA. RNA samples
were fractionated as described for panel A, except that cycloheximide
was excluded. The total nonselected RNA (column flowthrough [FT]) and
eluted RNA (eluate) were analyzed by Northern blot hybridization with
CD14 cDNA as a probe. An actin probe was included as a control for
loading variability.
|
|
Full-length or partial cDNAs were generated from U937 cells treated
with 1,25(OH)2D3 for 4 h to create a
plasmid library. Over 100,000 colonies were initially screened. After a
secondary screen, 162 candidate clones were selected to generate probes for Northern analysis of cells treated for 0, 4, and 12 h with 1,25(OH)2D3. Of these, induction of 20 clones
appeared to be increased fourfold or more within 4 h of treatment
(Fig. 3). After obtaining partial DNA
sequences, we assigned the clones to four different categories (Table
1). Class I clones correspond to known
genes. The first clone sequenced turned out to have identity to the
cyclin-dependent kinase (CDK) inhibitor
p21Cip1/Waf1. We have established that the p21
gene is transcriptionally induced by
1,25(OH)2D3 and that this induction
facilitates the differentiation of U937 cells into monocytes
(24). Other genes include those encoding the ribosomal
proteins S4 and L21, Ki antigen, and cyclin A, HoxA10,
Mad1, and CD14. Class II clones have no homology to known
proteins at the DNA level but do contain isolated regions with
similarity to known proteins at the amino acid level. Such clones
include clone 340, which has weak homology to TAN-1, the human homolog
of the Drosophila Notch protein (10), and clone 26, which has weak homology to NF-
B. Class III clones appear in the
database as expressed sequence tags. Class IV clones are clones that do
not appear in any database and are not homologous to any known gene.
Examples of the typical inductions observed with Northern blots for
members of each class are shown in Fig. 3.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
1,25(OH)2D3 induction of
candidate target gene RNAs in U937 cells. Shown are Northern blots of
RNA from U937 cells treated with 1,25(OH)2D3
for 0, 4, and 12 h. Clone numbers correspond to the nomenclature
in Table 1. Equal amounts of RNA were loaded in each lane, as indicated
by the representative membrane stained with methylene blue and showing
identical intensities of 28S and 18S rRNAs at each of three time
points.
|
|
HoxA10 induction by
1,25(OH)2D3.
On the basis of the
known or implied functions of some of the isolated
1,25(OH)2D3-inducible genes, we proceeded to
investigate the possible roles of these genes in facilitating the
differentiation of myeloid leukemic cells. For example, our previous
studies of p21 responsiveness to 1,25(OH)2D3 in
U937 cells established this gene as a direct transcriptional
target of VDR leading to growth arrest at the G1
phase of the cell cycle and differentiation towards a
monocyte/macrophage lineage. Likewise, owing to its identity as a
homeobox gene, HoxA10 was also an intriguing candidate for study both as a VDR target gene and as a trigger of differentiation.
To confirm that HoxA10 is transcriptionally regulated by
1,25(OH)2D3 and VDR, HoxA10 mRNA
accumulation in response to 1,25(OH)2D3 in the
presence and absence of cycloheximide was examined by Northern blotting. Consistent with the strategy used by the differential screen,
HoxA10 RNA was induced after 4 h in the absence or
presence of cycloheximide (Fig. 4A),
after which its levels decreased. To determine whether induction
was at the level of transcription, nuclear run-on assays were performed
with nuclei prepared from 1,25(OH)2D3-treated or untreated
U937 cells. As shown in Fig. 4B, hybridization with a HoxA10
probe indicated strong induction of transcription after 4 h of
ligand treatment. The kinetics of HoxA10 protein expression in response
to 1,25(OH)2D3 reveal detectable but low levels
at 4 and 12 h following the addition of ligand to U937 cells,
peaking at 36 h and gradually diminishing (but detectable) through
120 h of exposure to ligand (Fig. 4C). The transient kinetics of
HoxA10 expression may relate to its putative role in the
differentiation of myeloid cells (see Discussion).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
1,25(OH)2D3 induces HoxA10
expression in U937 cells. (A) Northern blot analysis of mRNA isolated
from exponentially growing U937 cells treated with
1,25(OH)2D3 (10 7 M), with or
without cycloheximide (CHX), for the indicated times. The methylene
blue-stained 18S band was used as a control for RNA loading. (B)
Nuclear run-on analysis of nuclear extracts isolated from cells grown
in the presence or absence of 1,25(OH)2D3.
Cells were harvested and nuclei were prepared 4 h after hormone or
ethanol addition. -Actin was used as a loading control. (C) HoxA10
protein levels following 1,25(OH)2D3 treatment.
HoxA10 protein was assayed by immunoblotting with anti-HoxA10 antibody
(Babco) with 20 µg of whole-cell extracts from cells treated with
1,25(OH)2D3 (10 7 M) for the
indicated times.
|
|
Transient HoxA10 overexpression facilitates differentiation of U937
cells.
The early 1,25(OH)2D3 induction of
HoxA10 expression and the role of the latter as a putative
transcription factor suggested that this event may, in fact, initiate
differentiation of U937 cells into monocytes/macrophages. We tested
this hypothesis by expressing full-length HoxA10 from a cytomegalovirus
(CMV) promoter following transient transfection of U937 cells with this
plasmid. To identify transfected cells and to normalize for
fluctuations in transfection efficiency, a CMV construct expressing GFP
was included in the same transfection. After 48 h,
GFP-positive cells were assayed for the appearance of the
monocyte/macrophage-specific cell surface marker CD11b. As a positive
control, cells were transfected with GFP and CMV-p21. As a
negative control, an empty CMV expression vector was
cotransfected with CMV-GFP and similarly assayed for both GFP and CD11b
expression. Figure 5 demonstrates that
the number of double-positive cells was significantly greater when CMV-HoxA10 was introduced into cells (Fig. 5B), compared to the CMV
vector (Fig. 5A). That is, the percentage of CD11b-positive cells,
normalized as a fraction of GFP-positive cells, increased specifically
when HoxA10 was overexpressed relative to the empty overexpression
vector. As expected, p21 also elicited expression of the
differentiation marker (Fig. 5C); however, coexpression of p21 and
HoxA10 did not appear to confer an additive or cooperative induction of
CD11b (data not shown). This suggests that while both proteins can
confer an effect on myeloid differentiation, they may do so through
independent pathways, requiring the cooperation of additional, distinct
factors.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 5.
Induction of differentiation of U937 cells by transient
overexpression of HoxA10 in the absence of
1,25(OH)2D3. U937 cells were transiently
cotransfected with an empty CMV vector [CMV( )] (A) or with CMV
expressing HoxA10 (B) or p21 (C), together with CMV-Green Lantern, a
reporter plasmid constitutively expressing GFP. Forty-eight hours
posttransfection, cells were harvested and extracts were prepared and
labeled with PE-coupled CD11b. FACS analysis was then carried out to
quantitate GFP (vertical axis) and CD11b fluorescent staining
(horizontal axis). Double-positive cells are shown in the upper right
quadrant; the fraction of CD11b-positive cells relative to the total
GFP-positive population in each experiment is shown as a percentage
below panels A to C. Each value is the mean of three independent
experiments. GFP was used to mark transfected cells (D) and to
normalize for fluctuations in transfection efficiencies in the empty
CMV vector, CMV-HoxA10, and CMV-p21 transfections. Results for
untreated and 1,25(OH)2D3-treated cells (48-h
treatment) were included in panels E and F as negative and positive
controls, respectively, for CD11b induction. FL, fluorescence.
|
|
HoxA10 is induced in MCF-7 cells by
1,25(OH)2D3 and facilitates cell cycle
arrest.
The human HoxA10 gene was originally cloned
from a U937 cell library (25) and found to be expressed
exclusively in myelomonocytic cell types (22). Using an
antibody raised against the C terminus of the HoxA10 protein
(34) (Fig. 4), we examined the expression of the protein in
several different cell lines and surprisingly detected it to varying
degrees in seven lines tested, ranging from HaCaT, an immortalized
keratinocyte cell line, to the MCF-7 line (data not shown). Apart from
U937 cells, MCF-7 was the only other cell type in which we found HoxA10
to be responsive to 1,25(OH)2D3 induction (Fig.
6A).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
HoxA10 is induced in MCF-7 cells by
1,25(OH)2D3 and facilitates cell cycle arrest.
(A) HoxA10 is induced by 1,25(OH)2D3 in MCF-7
cells. Whole-cell extracts were isolated from MCF-7 cells 0, 24, and
48 h after the addition of 10 8 M
1,25(OH)2D3. Twenty micrograms of total protein
was separated by SDS-polyacrylamide gel electrophoresis, transferred to
a polyvinylidine difluoride membrane, and probed with an anti-HoxA10
antibody. (B) MCF-7 cells are arrested in G1 by
1,25(OH)2D3. The DNA content of nuclei isolated
from MCF-7 cells that were either untreated or treated for 24 h with 10 8 M 1,25(OH)2D3 was
determined by FACS analysis after staining with propidium iodide. (C)
Transient ectopic overexpression of HoxA10 induces G1
arrest in MCF-7 cells. The cell cycle distribution of MCF-7 cells was
determined for cells that were cotransfected with an empty vector
[CMV( )] or CMV-HoxA10 together with CMV-GFP. GFP-positive cells
were sorted, cell cycle distribution based on DNA content was
determined by propidium iodide staining, and data were processed by
using the Multicycle program (Phoenix Flow Systems). Shown are the
averages of three separate experiments, and below are the DNA profiles.
Note that the frequency scales are different on the two graphs.
|
|
Treatment of MCF-7 cells with 1,25(OH)2D3
resulted in a strong G1-phase growth arrest after 24 h
(Fig. 6B). We therefore tested HoxA10's ability to arrest MCF-7
cell growth by using a strategy similar to that carried out for U937
cells (described in the legend to Fig. 5). Since MCF-7 cells are
already differentiated, we asked whether the ectopic overexpression
of HoxA10 could induce cell cycle arrest. CMV-HoxA10
and CMV-GFP were therefore used to cotransfect MCF-7 cells;
GFP-positive cells were sorted and analyzed for DNA content by
propidium iodide staining. Expression of HoxA10 indeed conferred a
significant decrease in the number of cells in S phase and an
accompanying higher G1-phase content relative to cells transfected with the CMV vector alone (Fig. 6C). Thus, HoxA10 expression and its action as a growth inhibitor do not appear to be
restricted to myeloid cell types.
 |
DISCUSSION |
We have described here a strategy for enriching for
immediate-early genes that are induced by
1,25(OH)2D3 in myeloid leukemic cells. The crux
of our strategy has been to bias for isolating the earliest targets of
this regulation, i.e., direct, transcriptionally regulated genes of
1,25(OH)2D3 and VDR. We incorporated into our screen three components that most likely increased the probability of
obtaining such targets: (i) a very short (4-h) pulse of the ligand
prior to isolating RNA; (ii) cycloheximide to block de novo protein
synthesis and thereby reduce the chance of isolating inducible genes
downstream; and (iii) the addition of 4-thiouridine during the 4-h
ligand treatment to permit the enrichment and isolation of only
those mRNA species synthesized during the 4-h exposure to
1,25(OH)2D3. We then screened by using a
standard differential approach with probes generated from
1,25(OH)2D3-treated and untreated cells.
However, in principle, this approach could easily be combined with any
of a number of current methods for isolating and cloning regulated
genes: differential display, subtraction, or suppressive subtractive
hybridization.
As is typical for any of these approaches, a number of the isolated
cDNAs are unknown and novel. Of these, some have intriguing but quite
weak homologies to known genes. For example, clone 340, which is
strongly induced by 1,25(OH)2D3, has some
partial amino acid sequence homology to TAN-1, the human homolog of the
Drosophila Notch protein (10), and clone 310 has
some similarity to Fos-related antigen. Some of the inducible cDNAs
contain Alu repeat sequences or transposable elements. But a
significant number of the isolated cDNAs are known genes encoding
proteins with interesting functions. Four of these genes, encoding
ribosomal proteins L21 and S4, Ki antigen, and cyclin A (Table 1),
might not be predicted to be upregulated during differentiation. The
cellular function of Ki antigen is unknown. It was originally
identified as a nuclear protein recognized by systemic lupus
erythematosus patient antisera (28, 29). Its sequence is
between 33 and 41% identical to PA28, an activator of the 20S
proteasome; both PA28 and Ki antigen are induced by gamma interferon at
the mRNA level (2, 13). What is surprising about the
induction of Ki antigen in myeloid cells by
1,25(OH)2D3 is that in mouse fibroblasts, its
expression mirrors that of c-myc, which is generally
associated with proliferation (28).
Similarily, increases in cyclin A are typically associated with cell
growth, not differentiation. In proliferating cancer cells in culture,
there is a striking positive correlation between the amount of cyclin A
mRNA and protein and the number of cells in S and G2/M
phase, so much so that cyclin A might be considered a marker for tumor
cell proliferation (9). To our knowledge, there is no report
that cyclin A is upregulated by an external signal during cell growth
arrest or differentiation. However, in our differentiation assay, we
consistently observed a transient burst of proliferation following
1,25(OH)2D3 treatment of U937 cells that
precedes growth inhibition and differentiation. This short increase in
proliferation is accompanied by increases in the levels of cyclin A,
cyclin D1, and cyclin E proteins (31a). We do not as yet
understand why differentiation might require an initial increase in
proliferation, but it may explain why a target like cyclin A was
isolated in the screen.
Three other known genes, p21Waf1/Cip1,
Mad1, and HoxA10, were scored as positive in the
differential screen and, based on their known functions, provide
varying degrees of insight into how differentiation is induced by
1,25(OH)2D3. We previously described the
identification of p21 as a
1,25(OH)2D3-inducible target gene by means of
this screen, and we subsequently established that the p21 gene is, in
fact, transcriptionally induced by 1,25(OH)2D3
and that this induction facilitates the differentiation of U937 cells
into monocytes/macrophages. Overexpression of p27 also leads to U937
differentiation (24). Thus, cell cycle arrest in
G1 gives way to differentiation, at least in this cell
type.
Mad1 is a heterodimeric partner of Max (5); Max in turn is a
requisite DNA binding partner of Myc (8). These two dimer species appear to have opposing biological effects: Myc-Max
heterodimers transactivate target genes and are associated with the
proliferative state (but also, paradoxically, with apoptosis) and
oncogenesis. Myc overexpression is sufficient to drive cells through
the cell cycle, and the Myc gene family has been implicated
in many types of human malignancies (3, 11). These effects
of Myc presumably occur through the action of Myc-Max heterodimers. In
contrast, a switch in Max dimer partners from Myc to Mad results in a
complex that has been associated with growth inhibition and
differentiation in a number of cell lines (4, 20, 36). Ayer
and Eisenman have shown that in U937 cells induced to differentiate
with phorbol esters, Mad protein levels are rapidly induced and are
accompanied by a switch from Myc-Max to Mad-Max heterodimers
(4). Thus, the induction of Mad1 by
1,25(OH)2D3 may be initiating a similar switch
that is required to alter the proliferative effects of Myc toward a
growth-inhibitory state.
The human homeobox gene HoxA10 was originally cloned in U937
cells and reported to have a myeloid-restricted expression pattern. Surveying normal and leukemic marrow samples, Largman and coworkers found that this gene is expressed in CD34+ normal marrow
cells but not in CD34
marrow cells or in mature
neutrophils, monocytes, and lymphocytes (22). Moreover, when
HoxA10 was overexpressed in murine bone marrow cells with a
retroviral vector, a significant increase in the number of colonies
formed containing megakaryocytes and blast cells with an absence of
macrophage and pre-B-lymphoid progenitor cells (34) was
observed. Taken together, these results suggest that the
HoxA10 gene is active in the early stages of myelopoiesis and is downregulated as myeloid cells mature and differentiate. It is
perhaps, then, somewhat surprising that when we transiently overexpressed HoxA10 in U937 cells independent of
1,25(OH)2D3, a significant degree of
macrophage-specific CD11b expression was detectable in the transfected
cells relative to the expression vector alone (Fig. 5). The
upregulation of HoxA10 in response to
1,25(OH)2D3 may serve to increase the
basal levels normally found in myeloid cells to further drive
differentiation, but this may require only a transient, early increase
in HoxA10 levels. Consistent with this, the kinetics of
HoxA10 mRNA induction in response to
1,25(OH)2D3 peak at 4 h following
addition of the ligand and subside thereafter (Fig. 4A).
The notion of central regulatory roles played by Hox genes
during hematopoiesis is not new. Homeobox gene products function as key
developmental switches in the determination of cell fate and tissue
identity during Drosophila embryogenesis (12,
23). Since hematopoiegenesis in many ways parallels
embryogenesis, it is reasonable to hypothesize that homeobox genes are
involved in hematopoietic differentiation. In fact, in surveys of human leukemic cell lines, lineage-specific expression patterns of
Hox genes have been observed (21). Moreover,
there are suggestions that mutations of homeobox genes might be
leukemogenic (33). That a ligand like
1,25(OH)2D3 is regulating a homeobox gene also has a precedent in the well-characterized effects of retinoic acid on
Hox genes in the mouse, whereby the genes are induced in a
linear cascade that reflects their arrayed organization on particular
chromosomes (18). Langston and Gudas have identified retinoic-acid-responsive elements in the Hoxa-1 gene
promoter (19), and they also showed that retinoic acid
failed to induce Hoxa-1 expression in a murine
differentiation-defective embryonal carcinoma cell line carrying a
mutant gene for RAR
(31). A retinoic-acid-responsive
element has also been characterized upstream of the mouse
Hoxd-4 gene (30). To our knowledge, our finding here that HoxA10 is induced by
1,25(OH)2D3 in what appears to be a direct
transcriptional induction is the first report of a Hox gene
regulated by this ligand. We recently sequenced over 4 kb of the human
HoxA10 upstream region from genomic YACs (3a), and we will determine whether functional vitamin D-responsive elements
reside in this region and are responsible for mediating 1,25(OH)2D3 induction.
HoxA10 may play a more generalized role in cellular
regulation beyond the myeloid lineage. Its mouse homolog,
Hoxa-10, is expressed in the developing limb bud and in the
gut and urogenital tract; its expression patterns are very similar to
that observed for the Drosophila homeotic complex,
Abdominal B (AbdB) (7). Recently,
Hoxa-10-deficient mice were generated (32). Male
homozygotes have severe defects in spermatogenesis, resulting in
sterility, and female homozygotes, which ovulate normally, are sterile
due to early embryonic death at day 3 postcoitus. In the mouse, then, this gene appears to play an important role in both male and female sterility and extends its role beyond hematopoiesis. Along these lines,
we found that the human HoxA10 protein is expressed in numerous cell
types and is induced by 1,25(OH)2D3 in breast
tumor MCF-7 cells, in addition to U937 cells. The overexpression of HoxA10 in MCF-7 cells results in G1 arrest and growth
inhibition. Thus the HoxA10 protein may be playing a central, early
role in growth control. The molecular mechanism whereby this putative transcription factor regulates cell growth and differentiation generally, and in response to hormonal ligands such as
1,25(OH)2D3 in particular, will undoubtedly be
an area of increasing attention.
 |
ACKNOWLEDGMENTS |
N.Y.R. and M.L. contributed equally to this work.
We thank T. Delohery, J. Wrana, D. Tenen, and A. Koff for important
suggestions and discussions and V. Bromleigh, G. Farmer, and
C. Rachez for comments on the manuscript. We are indebted to
J. Massagué, C. Largman, D. Tenen, K. Nilsson, and M. Uskokovic for various reagents used here.
This work was supported by NIH grants DK-45460 and DK-52621 to L.P.F.
and MSKCC Support Grant CA-08748. N.Y.R. was supported in part by a
fellowship from the Dutch NWO Talent Stipendium. L.P.F. is a Scholar of
the Leukemia Society of America.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Cell Biology
Program, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New
York, NY 10021. Phone: (212) 639-2976. Fax: (212) 717-3298. E-mail: l-freedman{at}ski.mskcc.org.
Present address: Dept. of Cell Biology, Baylor School of Medicine,
Houston, TX 77030.
 |
REFERENCES |
| 1.
|
Abe, E.,
C. Miyaura,
H. Sakagami,
M. Takeda,
K. Konno,
T. Yamazaki,
S. Yoshiki, and T. Suda.
1981.
Differentiation of mouse myeloid leukemia cells induced by 1,25-dihydroxyvitamin D3.
Proc. Natl. Acad. Sci. USA
78:4990-4994.
|
| 2.
|
Ahn, J. Y.,
N. Tanahashi,
K. Akiyama,
H. Hisamatsu,
C. Noda,
K. Tanaka,
C. H. Chung,
N. Shibmara,
P. J. Willy,
J. D. Mott,
C. A. Slaughter, and G. N. DeMartino.
1995.
Primary structures of two homologous subunits of PA28, a -interferon-inducible protein activator of the 20S proteasome.
FEBS Lett.
366:37-42.
|
| 3.
|
Amati, B., and H. Land.
1994.
Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation, and death.
Curr. Opin. Genet. Dev.
4:102-108.
|
| 3a.
| Anderson, E. C., N. R. Rots, and L. P. Freedman. Unpublished data.
|
| 4.
|
Ayer, D. E., and R. N. Eisenman.
1993.
A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation.
Genes Dev.
7:2110-2119.
|
| 5.
|
Ayer, D. E.,
L. Jretzner, and D. E. Eisenman.
1993.
Mad: a heterodimeric partner of Max that antagonizes Myc transcriptional activity.
Cell
72:211-222.
|
| 6.
|
Beadling, C.,
K. W. Johnson, and K. A. Smith.
1993.
Isolation of interleukin 2-induced immediate early genes.
Proc. Natl. Acad. Sci. USA
90:2719-2723.
|
| 7.
|
Benson, G. V.,
T.-H. E. Nguyen, and R. L. Maas.
1995.
The expression pattern of the murine Hoxa-10 gene and the sequence recognition of its homeodomain reveal specific properties of Abdominal B-like genes.
Mol. Cell. Biol.
15:1591-1601.
|
| 8.
|
Blackwood, E. M., and R. N. Eisenman.
1991.
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
Science
251:1211-1217.
|
| 9.
|
Brechot, C.
1993.
Oncogenic activation of cyclin A.
Curr. Opin. Genet. Dev.
3:11-18.
|
| 10.
|
Ellisen, L. W.,
J. Bird,
D. C. West,
A. L. Soreng,
T. C. Reynolds,
S. D. Smith, and J. Sklar.
1991.
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.
Cell
66:649-661.
|
| 11.
|
Evan, G. I., and T. D. Littlewood.
1993.
The role of c-myc in cell growth.
Curr. Opin. Genet. Dev.
3:44-49.
|
| 12.
|
Gehring, W. J., and Y. Hiromi.
1986.
Homeotic genes and the homeobox.
Annu. Rev. Genet.
20:147-173.
|
| 13.
|
Gray, C. W.,
C. A. Slaughter, and G. N. DeMartino.
1994.
PA28 activator protein forms regulatory caps on proteasome stacked rings.
J. Mol. Biol.
236:7-15.
|
| 14.
|
Hellstrom, E.,
K. H. Robert,
E. Soppi,
P. O. Putkoken, and G. Gahrton.
1989.
Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside, and interferon on bone marrow cells from patients with myelodysplastic syndrome.
Leuk. Res.
13:113-120.
|
| 15.
|
Honma, Y.,
M. Huzumi,
E. Abe,
K. Konno,
M. Fukushima,
S. Hata,
Y. Nishii,
H. F. DeLuca, and T. Suda.
1983.
1 ,25-dihydroxyvitamin D3 and 1 -hydroxyvitamin D3 prolong the survival time of mice inoculated with myeloid leukemia cells.
Proc. Natl. Acad. Sci. USA
80:201-204.
|
| 16.
|
Howell, A. L.,
T. A. Satukel,
C. D. Bloomfield,
F. R. Davey, and E. D. Ball.
1991.
High dose vitamin D for treatment of myelodysplasia: a pilot study.
Br. J. Haematol.
77:30-35.
|
| 17.
|
Kizaki, M., and H. P. Koeffler.
1992.
Differentiation-inducing agents in the treatment of myelodysplastic syndromes.
Semin. Oncol.
19:95-111.
|
| 18.
|
Langston, A. W., and L. Gudas.
1994.
Retinoic acid and homeobox gene regulation.
Curr. Opin. Genet. Dev.
4:550-555.
|
| 19.
|
Langston, A. W., and L. J. Gudas.
1992.
Identification of a retinoic responsive enhancer 3' of the murine gene Hox-1.6.
Mech. Dev.
38:217-228.
|
| 20.
|
Larsson, L. G.,
M. Pettersson,
F. Oberg,
K. Nillson, and B. Luscher.
1994.
Expression of mad, mxi1, max, and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc.
Oncogene
9:1247-1252.
|
| 21.
|
Lawrence, H. J., and C. Largman.
1992.
Homeobox genes in normal hematopoiesis and leukemia.
Blood
80:2445-2453.
|
| 22.
|
Lawrence, H. J.,
G. Sauvageau,
N. Ahmadi,
A. R. Lopez,
M. M. LeBeau,
M. Link,
K. Humphries, and C. Largman.
1995.
Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells.
Exp. Hematol.
23:1160-1166.
|
| 23.
|
Levine, M., and T. Hoey.
1988.
Homeobox proteins as sequence-specific transcription factors.
Cell
55:537-540.
|
| 23a.
|
Liu, M.
1996.
.
Ph.D. thesis.
Cornell University School of Medical Sciences, Ithaca, N.Y.
|
| 24.
|
Liu, M.,
M.-H. Lee,
M. Cohen, and L. P. Freedman.
1996.
Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.
Genes Dev.
10:142-153.
|
| 25.
|
Lowney, P.,
J. Corral,
K. Detmer,
M. M. LeBeau,
L. Deaven,
H. J. Lawrence, and C. Largman.
1991.
A human Hox 1 homeobox gene exhibits myeloid-specific expression of alternative transcripts in human hematopoietic cells.
Nucleic Acids Res.
19:3443-3449.
|
| 26.
|
Moore, M. A. S.
1987.
Growth and maturation factors in leukemia, p. 399-445. In
R. K. Oldham (ed.), Principles of cancer biotherapy.
Raven Press, New York, N.Y.
|
| 27.
|
Munker, R.,
A. Norman, and H. P. Koeffler.
1986.
Vitamin D compounds: effect on clonal proliferation and differentiation of human myeloid cells.
J. Clin. Invest.
78:474-480.
|
| 28.
|
Nikaido, T.,
K. Shimada,
Y. Nishida,
R. S. Lee,
A. B. Pardee, and Y. Nishizuka.
1989.
Loss in transformed cells of cell cycle regulation of expression of nuclear protein recognized by SLE patient antisera.
Exp. Cell Res.
182:284-289.
|
| 29.
|
Nikaido, T.,
K. Shimada,
M. Shibata,
M. Hata,
M. Sakamoto,
Y. Takasaki, and C. Sato.
1990.
Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus.
Exp. Immunol.
79:209-214.
|
| 29a.
|
Ollson, I.,
U. Gullberg,
I. Ivhed, and K. Nilsson.
1983.
Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1,25-dihydroxyvitamin D3.
Cancer Res.
43:5862-5870.
|
| 30.
|
Popperl, H., and M. S. Featherstone.
1993.
Identification of a retinoic acid response element upstream of the murine Hox-42 homeobox gene.
Mol. Cell. Biol.
13:217-265.
|
| 31.
|
Pratt, M. A. C.,
A. W. Langston,
L. J. Gudas, and M. W. McBurney.
1993.
Retinoic acid fails to induce the expression of Hox genes in differentiation-defective murine embryonal carcinoma cells carrying a mutant gene for alpha retinoic acid receptor.
Development
53:105-113.
|
| 31a.
| Rots, N. Y., and L. P. Freedman.
Unpublished data.
|
| 32.
|
Satokata, I.,
G. Benson, and R. Maas.
1995.
Sexually dimorphic sterility phenotypes in Hoxa10-deficient mice.
Nature
374:460-463.
|
| 33.
|
Shen, W.-F.,
K. Detmer,
D. A. Morgan,
C. Largman, and H. J. Lawrence.
1992.
Modulation of homeobox gene expression alters the phenotype of human hematopoietic cell lines.
EMBO J.
11:2445-2453.
|
| 34.
|
Thorsteindottir, U.,
G. Sauvageau,
M. R. Hough,
W. Dragowska,
P. M. Landsorp,
H. J. Lawrence,
C. Largman, and R. K. Humphries.
1997.
Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid differentiation.
Mol. Cell. Biol.
17:495-505.
|
| 35.
|
Woodford, T. A.,
R. Schlegel, and A. B. Pardee.
1988.
Selective isolation of newly synthesized mammalian mRNA after in vivo labelling with 4-thiouridine or 6-thiouridine.
Anal. Biochem.
171:166-172.
|
| 36.
|
Zervos, A. S.,
J. Gyuris, and R. Brent.
1993.
Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.
Cell
72:223-232.
|
Mol Cell Biol, April 1998, p. 1911-1918, Vol. 18, No. 4
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gemelli, C., Orlandi, C., Marani, T. Z., Martello, A., Vignudelli, T., Ferrari, F., Montanari, M., Parenti, S., Testa, A., Grande, A., Ferrari, S.
(2008). The Vitamin D3/Hox-A10 Pathway Supports MafB Function during the Monocyte Differentiation of Human CD34+ Hemopoietic Progenitors. J. Immunol.
181: 5660-5672
[Abstract]
[Full Text]
-
Hassan, M. Q., Tare, R., Lee, S. H., Mandeville, M., Weiner, B., Montecino, M., van Wijnen, A. J., Stein, J. L., Stein, G. S., Lian, J. B.
(2007). HOXA10 Controls Osteoblastogenesis by Directly Activating Bone Regulatory and Phenotypic Genes. Mol. Cell. Biol.
27: 3337-3352
[Abstract]
[Full Text]
-
Vigano, P, Lattuada, D, Mangioni, S, Ermellino, L, Vignali, M, Caporizzo, E, Panina-Bordignon, P, Besozzi, M, Di Blasio, A M
(2006). Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system.. J Mol Endocrinol
36: 415-424
[Abstract]
[Full Text]
-
Daftary, G. S., Taylor, H. S.
(2006). Endocrine Regulation of HOX Genes. Endocr. Rev.
27: 331-355
[Abstract]
[Full Text]
-
Masuda, S., Jones, G.
(2006). Promise of vitamin D analogues in the treatment of hyperproliferative conditions.. Molecular Cancer Therapeutics
5: 797-808
[Abstract]
[Full Text]
-
Du, H., Daftary, G. S., Lalwani, S. I., Taylor, H. S.
(2005). Direct Regulation of HOXA10 by 1,25-(OH)2D3 in Human Myelomonocytic Cells and Human Endometrial Stromal Cells. Mol. Endocrinol.
19: 2222-2233
[Abstract]
[Full Text]
-
Nagpal, S., Na, S., Rathnachalam, R.
(2005). Noncalcemic Actions of Vitamin D Receptor Ligands. Endocr. Rev.
26: 662-687
[Abstract]
[Full Text]
-
Asada, M., Ohmi, K., Delia, D., Enosawa, S., Suzuki, S., Yuo, A., Suzuki, H., Mizutani, S.
(2004). Brap2 Functions as a Cytoplasmic Retention Protein for p21 during Monocyte Differentiation. Mol. Cell. Biol.
24: 8236-8243
[Abstract]
[Full Text]
-
Evans, K. N., Bulmer, J. N., Kilby, M. D., Hewison, M.
(2004). Vitamin D and Placental-Decidual Function. Reproductive Sciences
11: 263-271
[Abstract]
-
Leroy, P., Berto, F., Bourget, I., Rossi, B.
(2004). Down-regulation of Hox A7 is required for cell adhesion and migration on fibronectin during early HL-60 monocytic differentiation. J. Leukoc. Biol.
75: 680-688
[Abstract]
[Full Text]
-
Fahnenstich, J., Nandy, A., Milde-Langosch, K., Schneider-Merck, T., Walther, N., Gellersen, B.
(2003). Promyelocytic leukaemia zinc finger protein (PLZF) is a glucocorticoid- and progesterone-induced transcription factor in human endometrial stromal cells and myometrial smooth muscle cells. Mol Hum Reprod
9: 611-623
[Abstract]
[Full Text]
-
Zehnder, D., Evans, K. N., Kilby, M. D., Bulmer, J. N., Innes, B. A., Stewart, P. M., Hewison, M.
(2002). The Ontogeny of 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Expression in Human Placenta and Decidua. Am. J. Pathol.
161: 105-114
[Abstract]
[Full Text]
-
Roig, E. A., Richer, E., Canonne-Hergaux, F., Gros, P., Cellier, M. F. M.
(2002). Regulation of NRAMP1 gene expression by 1{alpha},25-dihydroxy-vitamin D3 in HL-60 phagocytes. J. Leukoc. Biol.
71: 890-904
[Abstract]
[Full Text]
-
Taghon, T., Stolz, F., De Smedt, M., Cnockaert, M., Verhasselt, B., Plum, J., Leclercq, G.
(2002). HOX-A10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific transcription factor. Blood
99: 1197-1204
[Abstract]
[Full Text]
-
Ward, J. O., McConnell, M. J., Carlile, G. W., Pandolfi, P. P., Licht, J. D., Freedman, L. P.
(2001). The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D3-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D3 receptor. Blood
98: 3290-3300
[Abstract]
[Full Text]
-
Bromleigh, V. C., Freedman, L. P.
(2000). p21 is a transcriptional target of HOXA10 in differentiating myelomonocytic cells. Genes Dev.
14: 2581-2586
[Abstract]
[Full Text]
-
Rots, N. Y., Iavarone, A., Bromleigh, V., Freedman, L. P.
(1999). Induced Differentiation of U937 Cells by 1,25-dihydroxyvitamin D3 Involves Cell Cycle Arrest in G1 That Is Preceded by a Transient Proliferative Burst and an Increase in Cyclin Expression. Blood
93: 2721-2729
[Abstract]
[Full Text]
-
Freedman, L. P.
(1999). Transcriptional Targets of the Vitamin D3 Receptor–Mediating Cell Cycle Arrest and Differentiation. J. Nutr.
129: 581-581
[Abstract]
[Full Text]